|Bid||0.0850 x N/A|
|Ask||0.0900 x N/A|
|Day's Range||0.0900 - 0.0950|
|52 Week Range||0.0600 - 0.1900|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.Each Unit is comprised of one ...
Detroit, Michigan--(Newsfile Corp. - June 2, 2021) - Aion Therapeutic Inc (CSE: AION) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. We invite our shareholders and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration.About Benzinga
Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.